Note: This document contains side effect information about brentuximab. Some of the dosage forms listed on this page may not apply to the brand name Adcetris.
More frequent side effects include: peripheral motor neuropathy. See below for a comprehensive list of adverse effects.
Applies to brentuximab: intravenous powder for solution
Intravenous route (Powder for Solution)
John Cunningham (JC) virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving brentuximab vedotin.
Along with its needed effects, brentuximab (the active ingredient contained in Adcetris) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking brentuximab:
Incidence not known
Some side effects of brentuximab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to brentuximab: intravenous powder for injection
Very common (10% or more): Rash (up to 31%), pruritus (up to 19%), alopecia (up to 14), night sweats (up to 12%), dry skin (up to 10%)
Rare (less than 0.1%): : Stevens-Johnson syndrome (SJS) (including fatal outcomes), toxic epidermal necrolysis (including fatal outcomes)
Very common (10% or more): Nausea (up to 42%), diarrhea (up to 36%), abdominal pain (up to 25%), vomiting (up to 22%), constipation (up to 19%)
Postmarketing reports: Pancreatitis (including fatal outcomes)
Very common (10% or more): Neutropenia (any grade) (up to 78%), anemia (up to 52%), thrombocytopenia (up to 41%), lymphadenopathy (up to 11%)
Postmarketing reports: Febrile neutropenia
Frequency not reported: Anaphylactic reaction
Very common (10% or more): Weight decreased (up to 19%), decreased appetite (up to 11%)
Common (1% to 10%): Hyperglycemia
Very common (10% or more): Arthralgia (up to 19%), myalgia (up to 17%), back pain (up to 14%), pain in extremity (up to 10%)
Common (1% to 10%): Muscle spasms
Very common (10% or more): Peripheral sensory neuropathy (up to 56%), peripheral motor neuropathy (up to 23%), headache (up to 19%), dizziness (up to 16%)
Common (1% to 10%): Demyelinating polyneuropathy
Frequency not reported: Progressive multifocal leukoencephalopathy
Other side effects have included infusion related reactions (12%) including chills, nausea, dyspnea, pruritus, pyrexia and cough.
Very common (10% or more): Insomnia (up to 16%), anxiety (up to 11%)
Very common (10% or more): Upper respiratory infection (up to 47%), cough (up to 25%), dyspnea (up to 17%), oropharyngeal pain (up to 11%)
Postmarketing reports: Noninfectious pulmonary toxicity (including fatal outcomes)
Common (1% to 10%): Alanine aminotransferase/aspartate aminotransferase (ALT/AST) increased
Postmarketing reports: Hepatotoxicity
Very common (10% or more): Infection
Common (1% to 10%): Sepsis/septic shock, pneumonia, herpes zoster
Uncommon (0.1% to 1%): Oral candidiasis, pneumocystis jiroveci pneumonia, staphylococcal bacteremia
Postmarketing reports: Serious opportunistic infections
Uncommon (0.1% to 1%): Tumor lysis syndrome
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Adcetris